 Receptors, Estrogen
"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 3 | 2 | 5 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 3 | 3 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 4 | 1 | 5 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 3 | 5 | 8 | | 2004 | 6 | 4 | 10 | | 2005 | 1 | 6 | 7 | | 2006 | 2 | 2 | 4 | | 2007 | 6 | 6 | 12 | | 2008 | 9 | 5 | 14 | | 2009 | 0 | 4 | 4 | | 2010 | 6 | 5 | 11 | | 2011 | 2 | 6 | 8 | | 2012 | 7 | 7 | 14 | | 2013 | 2 | 6 | 8 | | 2014 | 4 | 5 | 9 | | 2015 | 4 | 8 | 12 | | 2016 | 9 | 3 | 12 | | 2017 | 6 | 6 | 12 | | 2018 | 4 | 5 | 9 | | 2019 | 2 | 4 | 6 | | 2020 | 4 | 7 | 11 | | 2021 | 7 | 3 | 10 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Commun Biol. 2022 04 19; 5(1):373.
-
Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 03; 61(3):359-371.
-
Jindal S, Pennock ND, Sun D, Horton W, Ozaki MK, Narasimhan J, Bartlett AQ, Weinmann S, Goss PE, Borges VF, Xia Z, Schedin P. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nat Commun. 2021 11 03; 12(1):6341.
-
Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 01; 21(1):48-57.
-
Borges VF. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When? J Clin Oncol. 2021 12 10; 39(35):3890-3896.
-
Cole SE, John EM, Hines LM, Phipps AI, Koo J, Ingles SA, Baumgartner KB, Slattery ML, McKean-Cowden R, Wu AH. Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities Study. Int J Cancer. 2022 01 15; 150(2):208-220.
-
Sottnik JL, Bordeaux EK, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Mol Cancer Res. 2021 08; 19(8):1270-1282.
-
Eom KY, van Londen GJ, Li J, Dahman B, Bradley C, Sabik LM. Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. BMC Cancer. 2021 May 01; 21(1):487.
-
Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3329-3338.
-
Gatti G, Betts C, Rocha D, Nicola M, Grupe V, Ditada C, Nuñez NG, Roselli E, Araya P, Dutto J, Boffelli L, Fernández E, Coussens LM, Maccioni M. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Res. 2021 03 25; 23(1):40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|